Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Blood
2018 Feb 22;1318:899-910. doi: 10.1182/blood-2017-05-786590.
Show Gene links
Show Anatomy links
Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin.
Aschemeyer S
,
Qiao B
,
Stefanova D
,
Valore EV
,
Sek AC
,
Ruwe TA
,
Vieth KR
,
Jung G
,
Casu C
,
Rivella S
,
Jormakka M
,
Mackenzie B
,
Ganz T
,
Nemeth E
.
???displayArticle.abstract???
Nonclassical ferroportin disease (FD) is a form of hereditary hemochromatosis caused by mutations in the iron transporter ferroportin (Fpn), resulting in parenchymal iron overload. Fpn is regulated by the hormone hepcidin, which induces Fpn endocytosis and cellular iron retention. We characterized 11 clinically relevant and 5 nonclinical Fpn mutations using stably transfected, inducible isogenic cell lines. All clinical mutants were functionally resistant to hepcidin as a consequence of either impaired hepcidin binding or impaired hepcidin-dependent ubiquitination despite intact hepcidin binding. Mapping the residues onto 2 computational models of the human Fpn structure indicated that (1) mutations that caused ubiquitination-resistance were positioned at helix-helix interfaces, likely preventing the hepcidin-induced conformational change, (2) hepcidin binding occurred within the central cavity of Fpn, (3) hepcidin interacted with up to 4 helices, and (4) hepcidin binding should occlude Fpn and interfere with iron export independently of endocytosis. We experimentally confirmed hepcidin-mediated occlusion of Fpn in the absence of endocytosis in multiple cellular systems: HEK293 cells expressing an endocytosis-defective Fpn mutant (K8R), Xenopus oocytes expressing wild-type or K8R Fpn, and mature human red blood cells. We conclude that nonclassical FD is caused by Fpn mutations that decrease hepcidin binding or hinder conformational changes required for ubiquitination and endocytosis of Fpn. The newly documented ability of hepcidin and its agonists to occlude iron transport may facilitate the development of broadly effective treatments for hereditary iron overload disorders.
Bonaccorsi di Patti,
A structural model of human ferroportin and of its iron binding site.
2014, Pubmed
Bonaccorsi di Patti,
A structural model of human ferroportin and of its iron binding site.
2014,
Pubmed
Callebaut,
Comprehensive functional annotation of 18 missense mutations found in suspected hemochromatosis type 4 patients.
2014,
Pubmed
Casu,
Minihepcidin peptides as disease modifiers in mice affected by β-thalassemia and polycythemia vera.
2016,
Pubmed
Chaston,
Evidence for differential effects of hepcidin in macrophages and intestinal epithelial cells.
2008,
Pubmed
Chung,
Hepcidin decreases iron transporter expression in vivo in mouse duodenum and spleen and in vitro in THP-1 macrophages and intestinal Caco-2 cells.
2009,
Pubmed
De Falco,
Iron refractory iron deficiency anemia.
2013,
Pubmed
Drakesmith,
Ironing out Ferroportin.
2015,
Pubmed
Drakesmith,
Resistance to hepcidin is conferred by hemochromatosis-associated mutations of ferroportin.
2005,
Pubmed
Détivaud,
Ferroportin diseases: functional studies, a link between genetic and clinical phenotype.
2013,
Pubmed
Ferbo,
Detection of a rare mutation in the ferroportin gene through targeted next generation sequencing.
2016,
Pubmed
Fernandes,
The molecular basis of hepcidin-resistant hereditary hemochromatosis.
2009,
Pubmed
Fraenkel,
Anemia of Inflammation: A Review.
2017,
Pubmed
Fung,
Thiol-derivatized minihepcidins retain biological activity.
2015,
Pubmed
Harrison-Findik,
Alcohol metabolism-mediated oxidative stress down-regulates hepcidin transcription and leads to increased duodenal iron transporter expression.
2006,
Pubmed
Hilton,
Molecular evolution and characterization of hepcidin gene products in vertebrates.
2008,
Pubmed
Le Gac,
Structure-function analysis of the human ferroportin iron exporter (SLC40A1): effect of hemochromatosis type 4 disease mutations and identification of critical residues.
2013,
Pubmed
Le Lan,
Sex and acquired cofactors determine phenotypes of ferroportin disease.
2011,
Pubmed
Lee,
Mild iron overload in an African American man with SLC40A1 D270V.
2012,
Pubmed
Liu,
Functional consequences of ferroportin 1 mutations.
2005,
Pubmed
Lok,
Iron overload in the Asian community.
2009,
Pubmed
Létocart,
A novel missense mutation in SLC40A1 results in resistance to hepcidin and confirms the existence of two ferroportin-associated iron overload diseases.
2009,
Pubmed
Mayr,
Identification of mutations in SLC40A1 that affect ferroportin function and phenotype of human ferroportin iron overload.
2011,
Pubmed
Mitchell,
Functional properties of human ferroportin, a cellular iron exporter reactive also with cobalt and zinc.
2014,
Pubmed
,
Xenbase
Nemeth,
Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization.
2004,
Pubmed
Olynyk,
Effects of HFE gene mutations and alcohol on iron status, liver biochemistry and morbidity.
2005,
Pubmed
Origa,
β-Thalassemia.
2017,
Pubmed
Pelucchi,
Novel mutations of the ferroportin gene (SLC40A1): analysis of 56 consecutive patients with unexplained iron overload.
2008,
Pubmed
Pietrangelo,
Hereditary hemochromatosis--a new look at an old disease.
2004,
Pubmed
Pietrangelo,
The ferroportin disease.
2004,
Pubmed
Praschberger,
Impact of D181V and A69T on the function of ferroportin as an iron export pump and hepcidin receptor.
2014,
Pubmed
Preza,
Cellular catabolism of the iron-regulatory peptide hormone hepcidin.
2013,
Pubmed
Preza,
Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload.
2011,
Pubmed
Qiao,
Hepcidin-induced endocytosis of ferroportin is dependent on ferroportin ubiquitination.
2012,
Pubmed
Rice,
Investigation of the biophysical and cell biological properties of ferroportin, a multipass integral membrane protein iron exporter.
2009,
Pubmed
Rivard,
Autosomal dominant reticuloendothelial iron overload (HFE type 4) due to a new missense mutation in the FERROPORTIN 1 gene (SLC11A3) in a large French-Canadian family.
2003,
Pubmed
Roy,
I-TASSER: a unified platform for automated protein structure and function prediction.
2010,
Pubmed
Santos,
Hereditary hemochromatosis: mutations in genes involved in iron homeostasis in Brazilian patients.
2011,
Pubmed
Schimanski,
In vitro functional analysis of human ferroportin (FPN) and hemochromatosis-associated FPN mutations.
2005,
Pubmed
,
Xenbase
Sham,
Autosomal dominant hereditary hemochromatosis associated with a novel ferroportin mutation and unique clinical features.
2005,
Pubmed
Stefanova,
Endogenous hepcidin and its agonist mediate resistance to selected infections by clearing non-transferrin-bound iron.
2017,
Pubmed
Taniguchi,
Outward- and inward-facing structures of a putative bacterial transition-metal transporter with homology to ferroportin.
2015,
Pubmed
Wallace,
Functional analysis and theoretical modeling of ferroportin reveals clustering of mutations according to phenotype.
2010,
Pubmed
Wallace,
A novel mutation in ferroportin implicated in iron overload.
2007,
Pubmed
Wallace,
Autosomal dominant iron overload due to a novel mutation of ferroportin1 associated with parenchymal iron loading and cirrhosis.
2004,
Pubmed
Yamakawa,
A Novel Phenotype of a Hereditary Hemochromatosis Type 4 with Ferroportin-1 Mutation, Presenting with Juvenile Cataracts.
2016,
Pubmed
Yang,
The I-TASSER Suite: protein structure and function prediction.
2015,
Pubmed
Zaahl,
Analysis of genes implicated in iron regulation in individuals presenting with primary iron overload.
2004,
Pubmed
Zhang,
Hepcidin regulates ferroportin expression and intracellular iron homeostasis of erythroblasts.
2011,
Pubmed
Zhang,
How does hepcidin hinder ferroportin activity?
2019,
Pubmed
